Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AJANTA PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AJANTA PHARMA BIOCON /
AJANTA PHARMA
 
P/E (TTM) x 35.5 27.7 128.0% View Chart
P/BV x 4.5 6.8 65.7% View Chart
Dividend Yield % 0.2 0.5 42.5%  

Financials

 BIOCON    AJANTA PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
AJANTA PHARMA
Mar-19
BIOCON /
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7071,422 49.7%   
Low Rs554898 61.7%   
Sales per share (Unadj.) Rs91.9233.5 39.4%  
Earnings per share (Unadj.) Rs16.744.0 38.0%  
Cash flow per share (Unadj.) Rs24.252.2 46.4%  
Dividends per share (Unadj.) Rs1.009.00 11.1%  
Dividend yield (eoy) %0.20.8 20.4%  
Book value per share (Unadj.) Rs101.6255.1 39.8%  
Shares outstanding (eoy) m600.0088.02 681.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.95.0 138.1%   
Avg P/E ratio x37.726.4 143.0%  
P/CF ratio (eoy) x26.122.2 117.3%  
Price / Book Value ratio x6.24.5 136.5%  
Dividend payout %6.020.5 29.2%   
Avg Mkt Cap Rs m378,330102,081 370.6%   
No. of employees `0006.16.8 90.2%   
Total wages/salary Rs m11,6534,307 270.6%   
Avg. sales/employee Rs Th8,994.33,022.6 297.6%   
Avg. wages/employee Rs Th1,900.7633.4 300.1%   
Avg. net profit/employee Rs Th1,635.3569.1 287.4%   
INCOME DATA
Net Sales Rs m55,14420,554 268.3%  
Other income Rs m1,444211 685.0%   
Total revenues Rs m56,58820,765 272.5%   
Gross profit Rs m15,8835,664 280.4%  
Depreciation Rs m4,478721 621.3%   
Interest Rs m70912 6,112.1%   
Profit before tax Rs m12,1405,143 236.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1231,273 166.8%   
Profit after tax Rs m10,0263,870 259.1%  
Gross profit margin %28.827.6 104.5%  
Effective tax rate %17.524.8 70.6%   
Net profit margin %18.218.8 96.6%  
BALANCE SHEET DATA
Current assets Rs m48,22811,812 408.3%   
Current liabilities Rs m30,3763,776 804.4%   
Net working cap to sales %32.439.1 82.8%  
Current ratio x1.63.1 50.8%  
Inventory Days Days6877 88.2%  
Debtors Days Days8682 104.8%  
Net fixed assets Rs m64,13014,398 445.4%   
Share capital Rs m3,000175 1,710.4%   
"Free" reserves Rs m57,98022,277 260.3%   
Net worth Rs m60,98022,452 271.6%   
Long term debt Rs m15,7667 238,878.8%   
Total assets Rs m121,92426,962 452.2%  
Interest coverage x18.1444.3 4.1%   
Debt to equity ratio x0.30 87,952.3%  
Sales to assets ratio x0.50.8 59.3%   
Return on assets %8.814.4 61.2%  
Return on equity %16.417.2 95.4%  
Return on capital %16.823.0 73.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50610,682 145.2%   
Fx outflow Rs m10,3992,102 494.7%   
Net fx Rs m5,1078,580 59.5%   
CASH FLOW
From Operations Rs m11,5463,748 308.1%  
From Investments Rs m-7,138-2,228 320.4%  
From Financial Activity Rs m-2,417-1,475 163.9%  
Net Cashflow Rs m2,10345 4,652.7%  

Share Holding

Indian Promoters % 40.4 73.8 54.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 1.6 541.9%  
FIIs % 10.7 7.6 140.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.0 117.1%  
Shareholders   109,995 20,968 524.6%  
Pledged promoter(s) holding % 0.0 4.4 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  FDC  GSK PHARMA  PANACEA BIOTECH  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 15, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS